纤维蛋白原与三阴性乳腺癌新辅助化疗疗效及预后相关性分析

The value of fibrinogen in therapeutic efficacy and prognosis of neoadjuvant chemotherapy in triple negative breast cancer

目的:评价三阴性乳腺癌新辅助化疗中纤维蛋白原(fibrinogen, FBG)与病理完全缓解(pathologic completeresponse, pCR)及预后的关系。方法:收集2000年1月至2017年10月于中国医学科学院肿瘤医院进行新辅助化疗的三阴性乳腺癌患者临床资料、血液检查结果及预后信息,分析基线FBG及其变化与临床病理特征、疗效及预后的关系。结果:共101名具有新辅助化疗前后FBG结果的三阴性乳腺癌纳入研究,获得pCR的患者基线FBG水平显著升高[(3.38±1.16) g·L^(-1) vs (2.92±0.75) g·L^(-1),(P<0.05)]。基线FBG为pCR的独立预测因素(OR=1.713,95%CI:1.004-2.935)。基线FBG及变化和RFS、OS无关(P>0. 05)。结论:基线FBG是有效预测三阴性乳腺癌新辅助化疗pCR的生物标志物。

Objective In the present study,we evaluated the association between FBG and pathologic complete response （pCR）,prognosis in triple negative breast cancer （TNBC）.Methods This was a retrospective study of TNBC patients who underwent neoadjuvant chemotherapy in Cancer Hospital Chinese Academy of Medical Sciences institution between January 2000 and October 2017. Clinicopathological data,fibrinogen before and after NAC and follow-up information were collected. The association of baseline FBG,FBG change with treatment efficacy and prognosis were analyzed.Results Totally 101 TNBC were enrolled in this study. The patients who achieved pCR had higher level of FBG than nonp CR [（3.38±1.16）g·L^-1 vs （2. 92±0.75） g·L^-1 ,P〈0.05）]. Baseline FBG was the independent predictive factor of pCR （ OR=1. 713,95%CI： 1.004-2. 935）. However,baseline FBG and FBG change were not associated with RFS and OS （ P〉0.05）.Conclusion Baseline FBG was a useful predictive biomarker of pCR in TNBC.